Belantamab mafodotin improved PFS — when combined with bortezomib and dexamethasone — as second-line treatment among patients with relapsed or refractory multiple myeloma, according to topline data from the agent’s manufacturer.
Belantamab mafodotin (Blenrep, GSK) is an antibody-drug conjugate comprised of a humanized B-cell maturation antigen monoclonal antibody conjugated to the cytotoxic agent auristatin F via a noncleavable linker.
The open-label phase 3 DREAMM-7 study assessed the efficacy and safety of belantamab mafodotin in combination with bortezomib and dexamethasone
